Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987287 | 0.87 | CA1 (0.52) | CA1CA2CA9CA14CA7 | |
| SCHEMBL983650 | 0.87 | CA1 (0.47) | CA1CA2CA9CA14CA7 | |
| SCHEMBL987509 | 0.87 | CA1 (0.47) | CA1CA2CA9CA14CA7 | |
| SCHEMBL986893 | 0.84 | CA1 (0.41) | CA1CA2CA9CA14CA7 | |
| SCHEMBL988435 | 0.84 | CA1 (0.45) | CA1CA2CA9CA14CA7 | |
| SCHEMBL987586 | 0.80 | CA1 (0.49) | CA1CA2CA9CA14CA7 | |
| SCHEMBL987510 | 0.79 | CA1 (0.48) | CA1CA2CA9CA14CA7 | |
| SCHEMBL986403 | 0.76 | DRD1 (0.52) | CA1CA2CA9CA14CA7 | |
| SCHEMBL983857 | 0.74 | CA1 (0.52) | CA1CA2CA9CA14CA7 | |
| SCHEMBL4669558 | 0.73 | CA1 (0.45) | CA1CA2CA9CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | claimed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | claimed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | claimed |
| EP-1732898-A1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | Analytecon S.A. (CH) | 2006-12-20 | — | — | EP | claimed |
| WO-2005087743-A1 | TETRAHYDROISOQUINOLINE-AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON S.A. (CH) | 2005-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | CA1 3524/4885CA2 3861/4885CA9 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.